MedTrace Logo

CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia

NCT04452396 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-12-12

No results posted yet for this study

Summary

Use of CGM to determine diagnosis in possible spontaneous or reactive hypoglycaemia.

Use of CGM to aid treatment optimisation in spontaneous or reactive hypoglycaemia

Conditions

  • Hypoglycemia, Reactive
  • Hypoglycaemia Night
  • Hypoglycemia Non-Diabetic
  • Hypoglycemia Unawareness
  • Insulinoma
  • Insulinoma; Malignant, Pancreas
  • Insulin Hypoglycemia
  • Insulin Resistance
  • Spontaneous Hypoglycemia
  • Neuro Endocrine Tumours

Interventions

DEVICE

use of continuous glucose monitoring

Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.

Sponsors & Collaborators

  • Barts & The London NHS Trust

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-03-01
Completion
2023-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452396 on ClinicalTrials.gov